Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS™. The official launch of MyPRS™ will take place at the 52nd Annual American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida on December 4th...
More...
More...